McGuire Christina, Cotter Kristina, Stransky Laura, Forgac Michael
Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, United States.
Biochim Biophys Acta. 2016 Aug;1857(8):1213-1218. doi: 10.1016/j.bbabio.2016.02.010. Epub 2016 Feb 22.
V-ATPases are ATP-driven proton pumps that function within both intracellular compartments and the plasma membrane in a wide array of normal physiological and pathophysiological processes. V-ATPases are composed of a peripheral V(1) domain that hydrolyzes ATP and an integral V(0) domain that transports protons. Regulated assembly of the V-ATPase represents an important mechanism of regulating V-ATPase activity in response to a number of environmental cues. Our laboratory has demonstrated that glucose-dependent assembly of the V-ATPase complex in yeast is controlled by the Ras/cAMP/PKA pathway. By contrast, increased assembly of the V-ATPase during dendritic cell maturation involves the PI-3 kinase and mTORC1 pathways. Recently, we have shown that amino acids regulate V-ATPase assembly in mammalian cells, possibly as a means to maintain adequate levels of amino acids upon nutrient starvation. V-ATPases have also been implicated in cancer cell survival and invasion. V-ATPases are targeted to different cellular membranes by isoforms of subunit a, with a3 targeting V-ATPases to the plasma membrane of osteoclasts. We have shown that highly invasive human breast cancer cell lines express higher levels of the a3 isoform than poorly invasive lines and that knockdown of a3 reduces both expression of V-ATPases at the plasma membrane and in vitro invasion of breast tumor cells. Moreover, overexpression of a3 in a non-invasive breast epithelial line increases both plasma membrane V-ATPases and in vitro invasion. Finally, specific ablation of plasma membrane V-ATPases in highly invasive human breast cancer cells using either an antibody or small molecule approach inhibits both in vitro invasion and migration. These results suggest that plasma membrane and a3-containing V-ATPases represent a novel and important target in the development of therapeutics to limit breast cancer metastasis. This article is part of a Special Issue entitled 'EBEC 2016: 19th European Bioenergetics Conference, Riva del Garda, Italy, July 2-6, 2016', edited by Prof. Paolo Bernardi.
V-ATP酶是一种由ATP驱动的质子泵,在细胞内区室和质膜中发挥作用,参与多种正常生理和病理生理过程。V-ATP酶由一个水解ATP的外周V(1)结构域和一个转运质子的整合V(0)结构域组成。V-ATP酶的调节组装是响应多种环境信号调节其活性的重要机制。我们实验室已经证明,酵母中V-ATP酶复合物的葡萄糖依赖性组装受Ras/cAMP/PKA途径控制。相比之下,树突状细胞成熟过程中V-ATP酶组装增加涉及PI-3激酶和mTORC1途径。最近,我们发现氨基酸调节哺乳动物细胞中V-ATP酶的组装,这可能是在营养饥饿时维持足够氨基酸水平的一种方式。V-ATP酶也与癌细胞的存活和侵袭有关。亚基a的不同异构体将V-ATP酶靶向不同的细胞膜,其中a3将V-ATP酶靶向破骨细胞的质膜。我们已经表明,高侵袭性的人乳腺癌细胞系比低侵袭性细胞系表达更高水平的a3异构体,并且敲低a3会降低质膜上V-ATP酶的表达以及乳腺癌细胞的体外侵袭能力。此外,在非侵袭性乳腺上皮细胞系中过表达a3会增加质膜V-ATP酶水平和体外侵袭能力。最后,使用抗体或小分子方法特异性去除高侵袭性人乳腺癌细胞中的质膜V-ATP酶会抑制体外侵袭和迁移。这些结果表明,质膜和含a3的V-ATP酶是开发限制乳腺癌转移治疗药物的一个新的重要靶点。本文是由Paolo Bernardi教授编辑的特刊“EBEC 2016: 第19届欧洲生物能量学会议,意大利里瓦德尔加尔达,2016年7月2 - 6日”的一部分。